immunocore-logo-2018
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
18 juin 2024 07h00 HE | Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
immunocore-logo-2018
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01 juin 2024 08h00 HE | Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
immunocore-logo-2018
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31 mai 2024 16h05 HE | Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
immunocore-logo-2018
Immunocore to present at the Jefferies Global Healthcare Conference
30 mai 2024 16h00 HE | Immunocore Holdings plc
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
TCR UK
TCR UK and Woya Digital Renew Marketing Partnership for 2024
10 mai 2024 12h32 HE | TCR UK
Birmingham, UK, May 10, 2024 (GLOBE NEWSWIRE) -- TCR UK and Woya Digital Renew Marketing Partnership for 2024 TCR UK is thrilled to announce the renewal of its marketing partnership with Woya...
immunocore-logo-2018
Immunocore reports first quarter financial results and provides a business update
08 mai 2024 07h00 HE | Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
Sport77 and J.A.S Mo
Sport77 and J.A.S Motorsport Announces New UK Motorsport Partnership
08 mars 2024 10h02 HE | Sport77 Ltd
London, UK, March 08, 2024 (GLOBE NEWSWIRE) -- Sport77 and J.A.S Motorsport are pleased to announce a new association that will increase support and access to Honda racing products in the United...
immunocore-logo-2018
Immunocore presented two posters at CROI 2024
05 mars 2024 16h30 HE | Immunocore Holdings Limited
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
immunocore-logo-2018
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
22 févr. 2024 07h00 HE | Immunocore Holdings Limited
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3...
Touring car driver Will Powell announces new partnership with Avon Tuning
Will Powell Announces New Racing Partnership With Road And Track Performance Specialists, Avon Tuning
11 févr. 2024 14h42 HE | Will Powell Racing
London, UK , Feb. 11, 2024 (GLOBE NEWSWIRE) -- Will Powell Announces New Racing Partnership Touring car driver Will Powell has announced a new partnership with renowned road and track...